Insmed Inc (INSM)vsXenetic Biosciences Inc (XBIO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
XBIO
Xenetic Biosciences Inc
$2.99
0.00%
HEALTHCARE · Cap: $6.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 20274% more annual revenue ($606.42M vs $2.98M). INSM leads profitability with a -2.1% profit margin vs -90.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
XBIO
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
18.1% revenue growth
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -40.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : XBIO
The strongest argument for XBIO centers on Price/Book, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : XBIO
The primary concerns for XBIO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while XBIO is a growth play — different risk/reward profiles.
XBIO carries more volatility with a beta of 2.32 — expect wider price swings.
XBIO is growing revenue faster at 18.1% — sustainability is the question.
XBIO generates stronger free cash flow (-242,682), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Xenetic Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?